Overview
APLM market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
No longer tradingThis symbol is retired in our registry: it no longer trades, so it has no live decision and cannot be traded here.
- Last Close
- $19.65
- Last Trading Day
- 2026-11-04
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 19.65
- H
- 19.65
- L
- 19.65
- C
- 19.65
- Vol
- 0.000000
Daily history from Jun 15, 2026
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- stale
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $19.65
- Previous Close
- $19.65
- Day High
- $19.65
- Day Low
- $19.65
- 52 Week High
- $27.50
- 52 Week Low
- $13.37
- 7 Day Return
- +0.00%
- 30 Day Return
- -18.19%
- 90 Day Return
- +12.41%
- 1 Year Return
- —
- Daily Notional Volume
- $0 Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.41 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -128.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $11.30 – $28.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $55.4M · P/B 2.21.